CHEK1 and ovarian carcinoma: HMGB3 deletion has been demonstrated to increase the cell sensitivity to cisplatin via the attenuation of ATR/CHK1/p-CHK1 DNA damage signaling pathway activation in ovarian cancer [22], suggesting an important role for HMGB3 in ovarian cancer.